Medpace Holdings, Inc. (MEDP)
Services-Commercial Physical & Biological Research · market cap $17.6B
Research and calibrated estimates, not financial advice — verify before acting.
No upcoming catalysts in our calendar.
| Asset | Phase | Indication |
|---|---|---|
| VI-0521 | Phase 3 | Obesity |
| Diazoxide Choline Controlled-Release Tablet | Phase 2 | Hypertriglyceridemia |
| [18F] Flutemetamol | Phase 3 | Healthy |
| MEN1703 | Phase 2 | Acute Myeloid Leukemia |
| Pyridoxamine Dihydrochloride | Phase 2 | Diabetic Nephropathy |
| Statin Therapy | Phase 2 | Hypercholesterolemia |
| Avacopan | Phase 2 | C3 Glomerulopathy (C3G) |
| AVM0703 | Phase 2 | Lymphoid Malignancies |
| MBN-101 | Phase 2 | Bacterial Infection |
| lerodalcibep | Phase 3 | Heterozygous Familial Hypercholesterolemia |
| Cefepime -/AAI101 | Phase 2 | Urinary Tract Infections |
| Pritelivir | Phase 3 | HSV Infection |
| dalcetrapib | Phase 3 | Acute Coronary Syndrome |
| CXA-10 | Phase 2 | Primary Focal Segmental Glomerulosclerosis |
| LIB003 | Phase 2 | LDL Cholesterol |
| cefepime/AAI101 combination | Phase 3 | Urinary Tract Infections |
| Cefepime-zidebactam (FEP-ZID) | Phase 3 | Complicated Urinary Tract Infection |
| rugonersen | Phase 3 | Angelman Syndrome |
| MultiStem | Phase 2 | Ischemic Stroke |
| Etripamil | Phase 2 | Paroxysmal Supraventricular Tachycardia (PSVT) |
Daily closes through 2026-11-19. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
- SEC filings — EDGAR filings for MEDP (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.
